Bausch Health Companies Inc - Q3 Earnings $BHC
Bausch Health Companies develops, manufactures, and markets products primarily in the therapeutic areas of gastroenterology, hepatology, neurology and dermatology, generic and branded generic pharmaceuticals, dentistry products, over-the-counter products, aesthetic medical devices, and eye health. BHC just reported Q3 earnings and significantly beat estimates. Q3 Earnings: EPS - $1.77 vs Est $1.26 (39.7% beat) Rev - $2.94B vs Est $2.75B (7% beat) Operating Income - $983m Operating cashflow - 581M Net Income - $436M Repaid 650M of debt reducing annual interest costs of $55m Authorized $50m of share repurchase Raised guidance for Q4. BHC has beat earnings in Q1, Q2 and now Q3 of 2026. Q2 Earnings price movement: On the Q2 earnings beat the stock ran from $4.4 to $7.35 in 2 days after ER release and opening flat. I expect a similar movement for this Q3 earnings release as the EPS and Revenue beat were both bigger then Q2. Why I am long: BHC has consistently beat earnings in 2026, actively
重要性:RSS 导入条目,等待编辑或代理补充市场影响解读。